A bill that provides important frameworks for breakthrough products in the next three to five years

You may not have noticed the recent Cures 2.0 Act introduced to Congress by two U.S. Representatives, Diana DeGette (D-CO) and Fred Upton (R-MI).

As a follow-up bill to the bipartisan 21st Century Cures Act signed into law in 2016, which accelerated healthcare innovation, this 2.0 version is particularly interesting for biomedical researchers, industry, and investors because it has the latest details on the new Advanced Research Projects Agency for Health (ARPA-H). …

Anna Du

Healthcare BD at University of California, San Francisco. Life sciences enthusiast. Currently writing about early-stage biopharma.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store